ORASURE TECHNOLOGIES, INC Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ORASURE TECHNOLOGIES, INC (OSUR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-03-09
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $53.05M, a 48.21% decline from fiscal 2023.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $102.44M, a 116.05% increase from fiscal 2022.
- ORASURE TECHNOLOGIES, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $47.41M, a 30.20% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $9.14M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $9.14M derived: sum of 3 quarters · filed 2026-03-09 | $43.82M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $9.14M derived: sum of 2 quarters · filed 2026-03-09 | $43.82M derived: sum of 3 quarters · filed 2026-03-09 | $53.05M 10-K · filed 2026-03-09 |
| 2024-09-30 | $9.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $43.82M derived: sum of 2 quarters · filed 2025-11-05 | $53.05M 10-Q · filed 2025-11-05 | $60.51M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $34.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $43.91M 10-Q · filed 2025-08-06 | $51.37M derived: sum of 3 quarters · filed 2026-03-09 | $119.04M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $9.23M 10-Q · filed 2025-05-07 | $16.69M derived: sum of 2 quarters · filed 2026-03-09 | $84.37M derived: sum of 3 quarters · filed 2026-03-09 | $84.37M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $75.14M derived: sum of 2 quarters · filed 2026-03-09 | $75.14M derived: sum of 3 quarters · filed 2026-03-09 | $102.44M 10-K · filed 2026-03-09 |
| 2023-09-30 | $67.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $67.68M derived: sum of 2 quarters · filed 2024-11-06 | $94.98M 10-Q · filed 2024-11-06 | $94.98M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $27.30M 10-Q · filed 2024-08-06 | $27.30M derived: sum of 3 quarters · filed 2025-03-07 | $51.70M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $27.30M 10-Q · filed 2024-05-09 | $27.30M derived: sum of 2 quarters · filed 2025-03-07 | $51.70M derived: sum of 3 quarters · filed 2025-03-07 | $62.58M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $24.40M derived: sum of 2 quarters · filed 2025-03-07 | $35.28M derived: sum of 3 quarters · filed 2025-03-07 | $47.41M 10-K · filed 2025-03-07 |
| 2022-09-30 | $24.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $35.28M derived: sum of 2 quarters · filed 2023-11-08 | $47.41M 10-Q · filed 2023-11-08 | $61.59M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $10.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $23.02M 10-Q · filed 2023-08-04 | $37.20M derived: sum of 3 quarters · filed 2024-03-11 | $47.20M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $12.13M 10-Q · filed 2023-05-10 | $26.32M derived: sum of 2 quarters · filed 2024-03-11 | $36.31M derived: sum of 3 quarters · filed 2024-03-11 | $46.31M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $14.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $24.18M derived: sum of 2 quarters · filed 2024-03-11 | $34.18M derived: sum of 3 quarters · filed 2024-03-11 | $67.92M 10-K · filed 2024-03-11 |
| 2021-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $20.00M derived: sum of 2 quarters · filed 2022-11-08 | $53.74M 10-Q · filed 2022-11-08 | $58.85M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $43.74M 10-Q · filed 2022-08-09 | $48.85M derived: sum of 3 quarters · filed 2023-03-03 | $63.85M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $33.74M 10-Q · filed 2022-05-10 | $38.85M derived: sum of 2 quarters · filed 2023-03-03 | $53.85M derived: sum of 3 quarters · filed 2023-03-03 | $85.65M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $20.10M derived: sum of 2 quarters · filed 2023-03-03 | $51.91M derived: sum of 3 quarters · filed 2023-03-03 | $107.72M 10-K · filed 2023-03-03 |
| 2020-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $46.80M derived: sum of 2 quarters · filed 2021-11-04 | $102.62M 10-Q · filed 2021-11-04 | $104.66M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $31.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $87.62M 10-Q · filed 2021-08-05 | $89.66M derived: sum of 3 quarters · filed 2022-03-01 | $125.48M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $55.81M 10-Q · filed 2021-05-06 | $57.85M derived: sum of 2 quarters · filed 2022-03-01 | $93.68M derived: sum of 3 quarters · filed 2022-03-01 | $104.68M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $37.87M derived: sum of 2 quarters · filed 2022-03-01 | $48.87M derived: sum of 3 quarters · filed 2022-03-01 | $93.49M 10-K · filed 2022-03-01 |
| 2019-09-30 | $35.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $46.83M derived: sum of 2 quarters · filed 2020-11-05 | $91.45M 10-Q · filed 2020-11-05 | $120.06M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $55.62M 10-Q · filed 2020-08-06 | $84.23M derived: sum of 3 quarters · filed 2021-03-01 | $122.38M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $44.62M 10-Q · filed 2020-05-11 | $73.23M derived: sum of 2 quarters · filed 2021-03-01 | $111.38M derived: sum of 3 quarters · filed 2021-03-01 | $151.41M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $28.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $66.75M derived: sum of 2 quarters · filed 2021-03-01 | $106.79M derived: sum of 3 quarters · filed 2021-03-01 | $152.68M 10-K · filed 2021-03-01 |
| 2018-09-30 | $38.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $78.18M derived: sum of 2 quarters · filed 2019-11-08 | $124.07M 10-Q · filed 2019-11-08 | $150.71M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $40.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $85.93M 10-Q · filed 2019-08-07 | $112.57M derived: sum of 3 quarters · filed 2020-03-02 | $136.59M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $45.89M 10-Q · filed 2019-05-09 | $72.53M derived: sum of 2 quarters · filed 2020-03-02 | $96.56M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $26.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $50.67M derived: sum of 2 quarters · filed 2020-03-02 | $69.25M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $24.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $42.61M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $18.59M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $30.42M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $22.97M 10-Q · filed 2017-11-09 | |||
| 2015-12-31 | $23.93M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |